Detalles de la búsqueda
1.
A phase 2 study of interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract.
Blood
; 141(12): 1389-1401, 2023 03 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-36399701
2.
Therapy-related acute lymphoblastic leukaemia in women with antecedent breast cancer.
Br J Haematol
; 2024 Mar 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38556836
3.
Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Am J Hematol
; 2024 May 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38800943
4.
Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Am J Hematol
; 2024 May 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38804599
5.
High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusions.
Am J Hematol
; 98(6): 848-856, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36880203
6.
Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia.
Cancer
; 128(3): 529-535, 2022 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34633671
7.
Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia.
Biol Blood Marrow Transplant
; 26(12): e322-e327, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32866594
8.
Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.
Biol Blood Marrow Transplant
; 26(6): 1084-1090, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32035275
9.
Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia.
Biol Blood Marrow Transplant
; 26(8): 1425-1432, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32416253
10.
Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center.
Biol Blood Marrow Transplant
; 26(2): 292-299, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31536825
11.
Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia.
Am J Hematol
; 95(10): 1193-1199, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32628327
12.
Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis.
Biol Blood Marrow Transplant
; 25(2): 287-292, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30227232
13.
Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Biol Blood Marrow Transplant
; 24(9): 1828-1835, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29753158
14.
Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia.
Biol Blood Marrow Transplant
; 23(7): 1117-1121, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28396160
15.
Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia.
Br J Haematol
; 196(6): e71-e74, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34931310
16.
Umbilical Cord Blood Transplantation Outcomes in Acute Myelogenous Leukemia/Myelodysplastic Syndrome Patients Aged ≥70 Years.
Biol Blood Marrow Transplant
; 22(2): 390-393, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26415559
17.
Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351).
Am J Hematol
; 96(6): E196-E200, 2021 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33719090
18.
Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.
Am J Hematol
; 94(10): E253-E255, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31259427
19.
A review of low dose interleukin-2 therapy in management of chronic graft-versus-host-disease.
Expert Rev Clin Immunol
; 20(2): 169-184, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37921226
20.
Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML.
J Clin Oncol
; 42(15): 1776-1787, 2024 May 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38324741